10月21日(路透社) - Galapagos NV:*GALAPAGOS宣布计划终止细胞疗法业务,作为公司持续转型的一部分*终止将影响全球365名员工*将关闭在荷兰、瑞士、美国和中国的多个基地*预计运营成本为1亿至1.25亿欧元,重组成本为1.5亿至2亿欧元*终止计划已获得Galapagos董事会批准,但不包括吉利德的董事*将于11月初与公司第三季度财报一起提供更新的2025年现金展望。 ((路透社投资简报;电子邮件:reutersinvestor.briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.